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We propose a joint model for binary and continuous responses using a latent
variable for the binary response. The observed continuous response and the latent
response are treated as correlated normals obeying a bivariate regression model. We
develop an EM algorithm to find maximum likelihood estimates for the parameters.
We perform the E–step analytically and use an iterative algorithm for the M–step.
The algorithm is applied to a prostate cancer clinical trial whose goal was
to assess therapeutic effects of diethylstilbestrol (DES) in advanced cancer patients
and to assess possible excess cardiovascular mortality. Therapeutic effects were
measured as prostatic acid phosphatase (PAP) levels follow–up and whether the
patient progressed to stage IV or died of cancer. The treatment reduced PAP levels
but not the incidence of cancer mortality within a six–month time frame. Higher
doses of DES were associated with increased risk of cardiovascular–related death.
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Biomedical studies typically have several endpoints which may be somehow
related. If these are all continuous, then multivariate regression is a natural way
to estimate the parameters jointly. Similarly, several categorical endpoints can be
jointly modeled using the multinomial distribution. If the endpoints are a mixture
of continuous and binary, they can be modeled separately using linear regression for
the continuous variables and probit or logistic regression for the binary ones. The
EM (expectation-maximization) algorithm can be used to link these two models,
thereby simultaneously estimating the regression parameters and the correlation
between the responses. We develop an EM algorithm specifically for this problem
using a latent normal variable model for the binary variable, and we apply it to a
prostate cancer dataset.
Our data comes from one of several prostate cancer studies from the Veterans
Administration Cooperative Urological Research Group (VACURG) in the 1960s
and 1970s. The studies tested the effects of various hormone therapies on the cancer,
and raised concerns about mortality due to cardiovascular disease associated with
one of the treatments, which was a daily dose of diethylstilbestrol (DES).
In Chapter 2 we give background information on the VACURG study, including
details about biomarkers that we used as variables in the analysis. We also describe
1
some of the methods of analyzing multiple endpoints of mixed type that have been
presented in the literature, and we outline the expectation maximization algorithm
and some of its extensions. In Chapter 3, we delineate our exploratory analyses of
the VACURG data, culminating with univariate regression models. We describe our
model and present our algorithm for estimating the maximum likelihood estimates in
Chapter 4, where we also present results of a simulation to examine the performance
of our algorithm. In Chapter 5, we apply the algorithm to the prostate data for two
key models. The first jointly models the log of PAP at follow–up and cancer death
or advance to stage IV cancer as the two response variables, and the second jointly
models log of PAP with cardiovascular death. Chapter 6 provides conclusions and





In this chapter we present background information on the VACURG study of
prostate cancer, treatment of multiple mixed-type endpoints, and the EM algorithm.
2.2 The VACURG Study
The Veterans Administration Cooperative Urological Research Group (VAC-
URG) was formed in 1960 and conducted three large-scale randomized prostate
cancer treatment studies (Byar 1973). The Group recruited United States mili-
tary veterans from 15 Veterans Administration Hospitals across the country. Each
study had two main parts: one on stage I and II patients and the other on stage
III and IV patients. The studies evaluated the effects of various hormone thera-
pies and surgeries that affect hormone levels. For stage I and II patients, Study
1 compared radical prostatectomy and placebo to radical prostatectomy and 5 mg
diethylstilbestrol (DES), which is a synthetic estrogen. Stage III and IV patients
were randomized to receive a placebo, 5 mg DES daily, orchiectomy and placebo,
or orchiectomy and DES. The first arm of Study 2, which began in 1967, on stage
I and II patients, received either placebo or prostatectomy and placebo. In the sec-
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ond arm, each patient was randomized to one of four treatment groups; one group
received a placebo, and the other three each took one of the following daily doses
of diethylstilbestrol (DES): 0.2 mg, 1 mg, or 5 mg. Study 3, which began in 1969,
employed the same treatment groups for stage I and II patients as did Study 2.
The stage III and IV patients received one of the following treatments: 1 mg DES,
Premarin, or Provera.
Patients were excluded if they had already begun some kind of treatment, and
the stage of their disease was determined by the physician before randomization.
Patients were classified as stage III if they had a local metastasis, and as stage IV if
they had either a distant metastasis or elevated levels of prostatic acid phosphatase
(PAP). PAP is an enzyme that is produced by the prostate that is used in staging
because 65% to 85% of patients with bone metastases have elevated levels of PAP
(Byar, Corle, and Brown 1988). Sixty percent of the patients classified as stage IV
in the VACURG studies were classified on the basis of elevated PAP levels in the
absence of other evidence of metastases (Byar, Corle, and Brown 1988).
The patients were followed for periods of up to nine years and assessed at
intervals by the physicians. During each follow-up visit many measurements were
taken from the patients.
Here we focus on the part of Study 2 which involved 506 patients who had
advanced to stages III and IV cancer. They were assessed at baseline and again at a
six-month follow-up. The men ranged from 48 to 99 years of age, with a mean age of
71.5. At the physician visits, the physicians recorded the extent of any metastases
the patient had, the degree to which the patient was experiencing pain, measures of
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activity level, whether the patient’s breast had enlarged or become tender as a result
of the therapy, whether the patient had changed treatments, estimated surface area
of the tumor, PAP, and Gleason histology, which was measured only at baseline. The
Gleason score is a tumor grade based on the microscopic character of the prostate
tissue.
Both at baseline and at the follow-up visit, the data collected included mea-
surements on the cardiovascular system because of concerns that were raised during
Study 1. Study 1 showed that patients on diethylstilbestrol did experience fewer
deaths due to prostate cancer, but the benefit was lessened because of increased risk
of death from diseases of the cardiovascular system (Bailar and Byar, 1970). These
measurements included the patient’s disease history, the blood pressure, heart rate,
and results of an electrocardiogram.
Variables of prognostic value would include age, since prostate cancer is a
disease that is associated with long-term exposure to the male hormones. Baseline
metastases and PAP would both be good predictors of a patient’s outcome because
they are associated with staging.
2.2.1 Endpoints
Death is a primary endpoint. Patients were coded as alive if they were still alive
at the end of the study, or the cause of death was classified as one of the following:
cancer of the prostate, heart or vascular diseases, stroke, pulmonary embolus, other
cancers, respiratory diseases, other specific non-cancer cause, unspecified non-cancer
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cause, or unknown. One expects the treatment to lower the risk of dying from
prostate cancer, but it turns out that the drug had toxic effects which increase
the incidence of cardiovascular- related deaths. An optimal treatment is one that
increases overall survival.
Aside from its value as a prognostic indicator, PAP can be used to measure
a patient’s tumor progression. Elevated levels of PAP are associated with progress
of the tumor. PAP values within an individual normally vary to within ±50% of
the mean for that individual (Byar, Corle, and Brown, 1988). For this reason,
only changes greater than 50% from baseline are considered significant during treat-
ment. These significant fluctuations in PAP levels reflect progress of the tumor or
improvement, which can be attributed to the treatment the patient is undergoing.
Another indicator of cancer progression would be the development of metas-
tasis.
The investigators in this study used intent-to-treat analysis, meaning that
patients were analyzed in the groups to which they were randomized, whether or
not they stayed on that particular treatment (Bailar and Byar, 1970). The patients’
urologists were able to change the patient’s treatment according to the patient’s best
interest. If the physician does decide to change the treatment or perform surgery,
that would indicate that the patient is not doing well.
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2.2.2 Summary of Findings
All three VACURG studies indicated that prostate cancer is responsive to
hormones, and they provided information about the risks of cardiovascular incidents
associated with estrogen therapies. These studies continue to be cited in discussions
of the complex issues of when to start hormone therapy and which patients should
be treated.
2.3 Regression Analysis of Multiple Mixed-Type Response Variables
A difficulty in modelling mixed-type outcomes is specifying their joint distrib-
ution. Several authors have considered the binary outcome as the manifestation of a
latent continuous random variable. Catalano and Ryan (1992) and Fitzmaurice and
Laird (1995) represented the joint distributions as products of a marginal and con-
ditional component. The parameters of the joint model have been estimated using
generalized estimating equations or stochastic EM algorithms, avoiding specifying
the likelihoods in closed form.
Catalano and Ryan (1992) developed a joint model for a continuous endpoint,
Y1, and a binary endpoint, Y
∗
2, by assuming that the binary event occurs only if a
latent normal random variable, Y2, exceeds a certain level. The joint distribution
of Y1 and Y
∗
2 was formed as the product of the marginal distribution of Y1 and
the conditional distribution of Y∗2|Y1. Their model was complicated because they
considered the case of correlation between individuals in clusters. They used quasi-
likelihood to estimate the regression parameters.
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Fitzmaurice and Laird (1995) also jointly considered a continuous and binary
response variable, but their interest was in estimating the marginal regression pa-
rameters, and they were uninterested in estimating the correlation between the two
responses. They also formed the joint distribution as a product of the marginal and
conditional distributions, but they used the binary endpoint as the conditioning
variable, in contrast to Catalano and Ryan’s model. They also used quasi-likelihood
to estimate the parameters.
Sammel, Ryan, and Legler (1997) modeled discrete and continuous outcomes
using latent variables, but their model accommodates the general case of the con-
tinuous variable from any regular exponential family and the latent variable from
any regular exponential family. The coefficients of the covariates can then be esti-
mated using MCEM, assuming the distributions of the latent variable and observed
continuous variable are known.
Geys et al. (2001) introduced two latent variable models for continuous and
discrete outcomes. One models the underlying latent variable using a Plackett
distribution. The other uses a normal distribution to model the underlying latent
variable. They also use pseudolikelihood methods to estimate the parameters.
Gueorguieva and Agresti (2001) also used a latent variable approach, using
a correlated probit model. They used Monte Carlo ECM to find the maximum
likelihood estimates of the parameters.
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2.4 The EM Algorithm
The Expectation Maximization (EM) algorithm is a procedure to compute
maximum likelihood estimates in cases of incomplete data. It is most useful in
situations in which, had the all the data been observed, the maximum likelihood
estimates would be easy to compute. The EM algorithm is an iterative procedure
in which each iteration consists of two steps: the expectation step, or E-step, and
the maximization step, or M-step.
Suppose one observes some incomplete data, X, and X∗ is the complete, unob-
servable data which comes from a distribution f(x; θ), which depends on a parameter
θ, and suppose that one is interested in finding the maximum likelihood estimate
for θ, θ̂. The E-step consists of computing the expectation of the complete-data log
likelihood, conditional on the observed data and the current guess of the parameters,
θ̂k:
Eθ̂k(ln f(X; θ)|X)
The M-step then maximizes the conditional expectation found in the E-step with
respect to θ. The value that maximizes the conditional expectation then becomes




The process repeats until the values converge.
The method was popularized by Dempster, Laird and Rubin (1977), who for-
mally defined the algorithm and provided various examples of applications, demon-
strating its versatility. They showed that each successive iteration of the algorithm
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increases the likelihood. Wu (1983) proved important properties of the algorithm.
He showed that the algorithm produces estimates that do converge to a value which
is a stationary point of the incomplete data likelihood, as long as the conditional
expectation of the complete data likelihood is continuous.
Although the EM algorithm does not have a built-in procedure for calculating
estimates of the variance-covariance matrix of the parameter estimates, Louis (1982)
described a procedure to find the observed information matrix which requires taking
derivatives only of the complete-data likelihood, which is usually more tractable than
that of the observed data. Several other schemes to estimate the variance have been
proposed since that of Louis. Some are described in detail in the book by McLachlan
and Krishnan (2008).
Various extensions and modifications of the EM algorithm have been pre-
sented to simplify calculations or decrease the the computation time. One is the
expectation-conditional maximization (ECM) algorithm, proposed by Meng and Ru-
bin (1993). The ECM algorithm is useful when the complete-data likelihood is
difficult to maximize. Instead of maximizing the conditional complete-data likeli-
hood in the M-step, a series of conditional maximization (CM) steps maximize the
conditional complete-data likelihood conditional on some of the parameters being
estimated. Since each maximization is over fewer parameters, the entire algorithm
can converge faster.
The ECM algorithm was extented to the ECME algorithm by Liu and Rubin
(1994). ECME represents ‘expectation-conditional maximization either,’ and in this
algorithm, some of the CM-steps maximize the conditional expectation of the actual,
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or observed-data likelihood, conditional on some of the parameters, rather than the
conditional expectation of the complete-data likelihood, conditional on some of the
parameters. Although the ECME can be difficult to program because it involves the
observed-data likelihood, the total computation time can be considerably reduced.
In some situations, the E-step can be difficult because of the integration in-
volved in computing the expectation of the likelihood. In this case, one may simulate
the missing data from the conditional distribution of the missing data, given the ob-
served data and the current estimate of the parameters. This approach, called Monte
Carlo EM (MCEM), was suggested be Wei and Tanner (1990). It uses the principle
of Monte Carlo integration to estimate conditional expectation of the complete-data
loglikelihood by taking the empirical loglikelihood based on the simulated sample.
Then this approximated expectation is maximized in the M-step. For the other EM
extensions mentioned here, ECM and ECEM, the attractive property of monotoni-
cally increasing sequence of incomplete likelihoods continues to hold as it does with
EM itself. This is not true of MCEM because of the Monte Carlo error associated
with the introduction of sampling within the E-step. This property is recovered with
high probability using Caffo et al.’s (2005) ascent-based MCEM, which determines
the Monte Carlo sample size at each E-step according to the data.
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Chapter 3
Exploratory Analysis of Prostate Data
3.1 Overview
We did a number of exploratory analyses on the data. Here we present those
analyses that motivate our model. In Section 3.2 we describe the contents of the data
and how we handled discrepancies we found. Then we provide summary statistics
in Section 3.3. Important endpoints are described in Section 3.4, and we develop
regression models for each of those endpoints in Section 3.5.
3.2 Structure of the Data
The data consists of two records each for 506 patients enrolled in the trial. The
first observation is labeled as the “initial history,” or baseline set of measurements.
The next record was taken at follow-up, which occurred about six months after the
initial appointment. This study began in 1967 and followed some patients for more
than ten years.
There were 292 stage III patients and 214 stage IV patients. They were ran-
domized to four groups as shown in Table 3.1. Some of the measurements recorded
were age, height, weight, the date of the exam, basic disease history, whether the
patient had any matastases, whether the patient was experiencing dilation of the
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upper urinary tract, the level of prostatic acid phosphatase, presence and extent of
pain, level of hemoglobin, activity level, presence of breast tenderness or enlarge-
ment, which are side effects of DES, blood pressure, heart rate, electrocardiogram
results, and cause of death if died on study. Cholesterol and level of alkaline phos-
phatase were recorded in some patients, but there were so many missing values of
these variables that they were not used in any of our analyses. This was a multicen-
ter study; one of the variables recorded for each patient was at which of 15 Veterans
Administration Hospitals the patient was seen.
Table 3.1: Treatment Group Randomization by Stage
Dose in Milligrams
Placebo 0.2 1.0 5.0
Stage
III 75 73 73 71
IV 53 52 55 54
There were fairly detailed records of whether the patient was on or off study
and why; the patients were categorized into on study, off study or died on study,
off study because the patient received no treatment or not the assigned treatment,
or off study because the patient was found to not have met the requirements for
enrollment in the study. For each patient who was not recorded as on study, an
explanation was provided, such as “patient too ill to continue study treatment,” or
“treated before placed on study.” The frequencies for each reason are shown in Table
3.2. We excluded from the analysis 20 patients who were removed from treatment
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or who should never have been enrolled in the study, and from this point on, our
analyses reflect the group excluding those 20 patients. For the patients that we
analyzed, we regarded their six–month follow–up record as occurring at six months
after beginning treatment, even if they had expired while on–study prior to the
six–month follow–up appointment.
Table 3.2: Patients Excluded From Analyses
Frequency
Patient psychotic or otherwise refuses treatment 1
Patient left area with no contact information 1
Previous hormone treatment 1
Malignant prostate lesion other than carcinoma 1
Treated before placed on study 2
Stage misclassified 10
Protocol violated; no pre-treatment workup 2
Drug violation or treatment violation 2
Nine patients had missing values of PAP measured at follow-up. PAP values
within an individual vary to within ±50% of the mean for that individual (Byar,
Corle, and Brown 1988). Seventy patients had identical values recorded for the
level of PAP at baseline and at follow-up. This was a surprising finding since the
probability that such a variable quantity would equal the same amount on two
occasions six months apart is zero. This might possibly be due to a missing value
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at the follow-up that was imputed from the baseline measurement. However, for
those patients who had the same values coded for both baseline and follow-up PAP,
54% died on study, while only 14% of the total group died on study. We conduct
analyses both with and without these patients.
3.3 Basic Characteristics of the Patients
Summary statistics for the patients’ ages are shown in Table 3.3. They are
given by stage.
Table 3.3: Age by Stage
n x̄ s.d. min. max.
Stage
III 243 71.82 6.69 49 89
IV 172 71.40 7.11 48 85
The number of patients at each Veterans Administration hospital varied. The
hospital with the most patients in the study was the one in Minneapolis, which had
119 patients. The one with the fewest was Omaha, which had five patients. The
median number of patients was 27.
In all, 59 patients died during the time frame our data covers. Figure 3.1
shows the number of deaths due to prostate or other cancers, cardiovascular events,
and other causes, by each dose group and by stage. There were not many deaths,
but we can see that there were more cancer deaths for stage IV than for stage III,
15
which is to be expected.
Figure 3.1: Frequency of Different Causes of Death by Dose and by Stage







































We would like to quantify how well the study drug affects the progression of
the prostate cancer as well as quantify any toxicity.
Dying of prostate cancer would certainly be the primary endpoint of interest.
Death due to other cancers would be strongly related. Developing new metastases
would indicate disease progression, as would a change in treatment. We constructed
16
a binary endpoint to reflect progression of the prostate cancer which is equal to one
if the patient died of prostate or some other cancer, developed a new metastasis,
had a change in treatment, or had surgery while on study.
As discussed in 2.2.1, prostatic acid phosphatase (PAP) is an excellent tumor
marker. The follow-up PAP levels had a skewed distribution, but they looked more
symmetric on a log scale. Byar (1973) studied the effects of the different doses of
DES on PAP, and he also looked at the effects on testosterone levels and on the size
of the prostate as determined by rectal examination. We do not have access to the
testosterone levels of the patients, but we did look at surface area of the prostate as
a response.
The first VACURG study revealed that DES had toxic effects which caused
cardiovascular disease. To quantify the effect of the toxicity and how it relates to
dose, we looked at another binary endpoint which indicates death due to cardiovas-
cular causes. We included death from heart or vascular diseases, death from stroke,
and death from pulmonary embolus, following Byar (1973).
3.5 Model Selection
We fitted models for three endpoints discussed in Section 3.4: the log of the
PAP level at follow-up, the binary indicator of cancer progression, and cardiovascular-
related death.
We fitted models to the data with and without the 70 patients for which the
baseline PAP was equal to the follow-up PAP. Including these observations in the
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model for the response of log of PAP at follow-up will tend to have a flattening effect
of the regression curve. One expects that the higher the dose, the lower the log of
PAP, yet for these patients, their follow-up PAP is the same as their baseline PAP.
So the effect of including these patients will be to underestimate the effect of dose
on log of PAP at follow-up. However, as we noted in Section 3.2, these patients were
more likely to have died than the other patients in the study. Not including these
patients could bias the results because it would lower the estimated probability of
death.
For the log of PAP at follow-up, to which we will refer here as ‘logpap2,’ we
fitted a linear regression model using complete-case analysis. We looked at various
predictors starting with the dose level, stage, and the baseline PAP level. However,
staging in this study was performed using the baseline level of PAP and presence of
distant metastasis (Byar, Corle, and Brown 1988), so that stage and baseline PAP
were highly correlated. For this reason, stage was not a significant predictor in the
presence of PAP, so we excluded it from the model. We looked at Gleason histology,
which was an ordinal variable, but it was correlated with the log of initial PAP. The
sample correlation coefficient was 0.24 with p-value less than 0.0001 for the test of
the null hypothesis that the correlation is zero. Age was a significant predictor with
a negative coefficient, so that the older a patient is, the less his PAP was at follow-
up. This may be because cancer generally progresses more slowly in older patients.
Dose was highly significant with a negative coefficient, showing that higher doses
do reduce levels of PAP, which would suggest that the drug is having an effect on
the cancer. Dose squared was also significant, so we retained it along with dose,
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age, and logpap. Tables 3.4 and 3.5 show the coefficient estimates and estimated
standard errors along with test statistics p-values for tests of difference from zero
for the individual coefficients, both with and without those patients with identical
values for baseline and follow-up PAP. The value of R2 was 0.56, or 0.53 excluding
the patients with imputed levels of PAP. We did not find that hospital location was
a good predictor; the F -test of a better model including location versus the model
shown in Table 3.5 had a p-value of 0.1563. A Q-Q plot of the residuals is given in
Figure 3.2. There is some departure from normality because of the heavy tails of
the distribution, as evidenced by the increased slope at the edges of the curve.
Table 3.4: Model: logpap2 = β0 + β1 logpap + β2 dose + β3 dose
2 + β4 age + error,
including patients with imputed values of PAP
Variable Estimate s.e. T-test statistic p-value
intercept 1.04 0.53 1.98 0.0484
logpap 0.69 0.03 21.08 < 2e− 16
dose -0.99 0.16 -6.00 4.49e− 9
dose2 0.15 0.03 4.90 1.41e− 6
age -0.01 0.01 -1.65 0.0997
Surface area was also good outcome variable, but we did not find covariates
to fit a model that was superior to logpap2. We display the model in Table 3.6.
In fitting the binary prostate cancer progression variable, which we refer to as
‘binend,’ we used probit regression, again using complete-case analysis. We started
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Table 3.5: Model: logpap2 = β0 + β1 logpap + β2 dose + β3 dose
2 + β4 age + error,
excluding patients with imputed values of PAP
Variable Estimate s.e. T-test statistic p-value
intercept 1.54 0.59 2.61 0.0095
logpap 0.67 0.04 17.99 < 2e− 16
dose -1.07 0.19 -5.71 2.44e− 8
dose2 0.16 0.04 4.52 8.88e− 6
age -0.02 0.01 -2.28 0.0232
out with logpap and dose as predictors. Dose did not turn out to be significant,
which may be because this model is based on the number of events within six
months, which is a relatively short period of time. Logpap was a good predictor,
as was surface area of the prostate. Hemoglobin was significant, with a negative
coefficient, meaning that patients who started out with a higher level of hemoglobin
were less likely to have binend equal to one. Results for this model are given in
Table 3.7.
For the cardiovascular-related death outcome, which we label ‘carddeath,’ for
brevity, we investigated age, history of cardiovascular disease, dose, electrocardio-
gram, and hemoglobin as predictors in a probit regression model. Age did turn out
to be significant, as expected, since this type of disease is associated with aging.
Also, a history of cardiovascular disease was a good predictor of carddeath. The
coefficient for dose was significant and had a positive sign, showing that the dose
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Table 3.6: Model: surface area 2 = β0 + β1 logpap + β2 dose + β3 dose
2 +
β4 surface area + error
Variable Estimate s.e. T-test statistic p-value
intercept 5.34 0.85 6.31 7.25e− 10
logpap 0.83 0.29 2.84 0.0047
dose -7.41 1.42 -5.23 2.67e− 7
dose2 1.22 0.27 4.55 6.98e− 6
surface area 0.61 0.04 17.46 2e− 16
increases, so does the incidence of carddeath. No other variables entered the model.
Table 3.8 shows the results of the model.
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Table 3.7: Model: P [binend = 1] = Φ(β0 + β1 logpap + β2 surface area + β3 dose +
β4 hemoglobin)
Variable Estimate s.e. T-test statistic p-value
intercept -0.07 0.52 -0.14 0.88633
logpap 0.13 0.05 2.82 0.00480
surface area 0.02 0.01 3.01 0.00265
dose 0.02 0.04 0.45 0.65227
hemoglobin -0.09 0.04 -2.29 0.02210
Table 3.8: Model: P [carddeath = 1] = Φ(β0 + β1 cardiodisease + β2 age + β3 dose)
Variable Estimate s.e. Z-test statistic p-value
intercept -5.93 1.54 -3.85 0.000116
cardio disease 0.88 0.24 3.64 0.000274
age 0.05 0.02 2.41 0.015872
dose 0.11 0.05 2.39 0.016737
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Figure 3.2: QQ Plot of Residuals for Logpap2 Model


























Parameter Estimation Using the EM Algorithm
4.1 Overview
From Chapter 3, the most important endpoints that emerged from our ex-
ploratory analyses were prostatic acid phosphatase, occurrence of cardiovascular-
related death, and progression of the prostate cancer as evidenced by new metas-
tases, death from cancer, or a change in treatment. The first is continuous and, after
a log transformation, easily lends itself to analyses using ordinary least squares. The
latter two are binary, and can be modeled by logistic or probit regression. However,
our interest lies in the joint distribution of the pair to allow for dependence between
the two response variables. To this end, we can view the cardiovascular event as the
observable product of some underlying disease process which follows a continuous
distribution. If we condition on the value of the variables that we actually observe,
we can use the expectation-maximization (EM) algorithm to find the maximum
likelihood estimates of regression coefficients and variances.
The EM algorithm alternates between the E-step and the M-step. The E-step
consists of taking the conditional expectation of the log likelihood of the complete
model, given the value of the observed data. We compute this expectation analyti-
cally in Section 4.4. The M-step finds the values of the parameters that maximize
the expectation found in the E-step. In Section 4.5, we describe our maximization
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process. The maximum likelihood estimates are then substituted into the expecta-
tion, beginning a new iteration. We investigate the performance of the algorithm
in Section 4.6. We outline a procedure to estimate standard errors of the estimates
using bootstrap sampling in Section 4.7.
4.2 Model
For each individual, we have two endpoints. One is continuous, and one is
binary. The data are (Y1i, Y2i,x1i,x2i), i = 1, . . . , n, where (Y1i, Y2i) is the the row
vector of endpoints for the ith observation, and x1i and x2i are vectors of covariates
consisting of the ith row of X1 and X2, respectively. Let Y1 be the n-dimensional
vector of the continuous endpoints and let Y2 be the vector of binary responses. We
view the binary endpoint as partial information about an unobservable continuous
random variable, Y∗2. Specifically, Y2i = I{Y ∗2i>0}. Let Y = [Y1,Y2] be the matrix
of observable data, and let Y∗ be the matrix of the complete data. We assume
a joint multivariate normal distribution of Y1 and Y
∗
2 having within-observation
correlation coefficient ρ. We assume that E[Y1] and E[Y
∗
2] are linear functions of
the covariate matrices X1 and X2, respectively, so that we have the the following
linear models:
Y1i = x1iβ1 + ε1i
Y ∗2i = x2iβ2 + ε2i



















We want to estimate the parameters β1, β2, ρ, and σ
2
1. Let θ = {β1, β2, ρ, σ21}.
4.3 Constructing the Likelihood Function






















Since E(Y1) = X1β1 and E(Y
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where xki is a row vector consisting of the i
th row of Xk.
We use the EM algorithm to find the maximum likelihood estimate of θ.
4.4 The E-Step: Expectation of L Given the Observable Data
We take the conditional expectation of the complete data log likelihood ana-
lytically. We condition on the observed data, Y. Recall that Y2i is 1 when Y
∗
2i is
positive, and zero otherwise. Observe that





so that once the value of Y2 is observed, the next two relations follow, and we see
that there is not enough information in the data to estimate σ2 separately. For this





The conditional expectation of the complete data log likelihood is
















































2i − x2iβ2|Y1,Y2). (4.5)
In order to find the expectations in (4.2)–(4.5), we present the following lemma:
Lemma 1. Let Z1, Z2 be standard normal random variables with correlation coeffi-
cient ρ. Then
(i)















E(Z22 |Z1 = z1, Z2 > c) =
































E(Z22 |Z1 = z1, Z2 < c) =





















































































1− ρ2)φ(w) dw dz1.
Multiplying the terms and noting that
∫


































After using the Mean Value Theorem and taking limits, we obtain (i).






















As before, we complete the square in the exponential and make the change of vari-
ables w = (z2 − ρz1)/
√










1− ρ2)2φ(w) dw dz1.
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We expand the square. The integral of the linear term is evaluated as in (i), and






















The calculations for (iii) and (iv) are similar to those of (i) and (ii), except
the limits of the inner integrals in an expression such as I1 are from z2 = −∞ to
z2 = c.






y∗2i − x2iβ̂2 + (x2iβ̂2 − x2iβ2) |y1i ,y∗2i > 0
)






,y∗2i − x2iβ̂2 > −x2iβ̂2
)
.




2i − x2iβ2|Y1,Y2) = x2iβ̂2 − x2iβ2 + E(z2i|z1i, z2i > c).
Using the results of Lemma 1(i), we have that the expectation in (4.3) is
Eθ̂(y
∗














since under the condition that θ̂ = θ, the correlation between z1i and z2i is ρ̂.
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[y∗2i − x2iβ̂2 + (x2iβ̂2 − x2iβ2)]2 |y1i ,y∗2i > 0
)
.







z22i + 2z2i(x2iβ̂2 − x2iβ2) + (x2iβ̂2 − x2iβ2)2|z1i, z2i > c
)
= (x2iβ̂2 − x2iβ2)2 + 2(x2iβ̂2 − x2iβ2)Eθ̂(z2i|z1i, z2i > c) + Eθ̂(z22i|z1i, z2i > c).





































Similar calculations yield the following for the expectation in (4.5):
Eθ̂(y
∗




















































4.5 The M-Step: Maximizing with Respect to the Parameters
The conditional expectation of the complete data likelihood (4.1) is a function
of the parameters, β1, β2, ρ, and σ1, their estimated values from the previous EM
iteration, β̂1, β̂2, ρ̂, and σ̂1, and the observed data, Y1, Y2, X1, and X2. The
M-step involves finding the parameter vector θ that maximizes this function. We
devised an iterative two-part algorithm in R to find the estimates that maximize
the conditional expectation (4.1).
We first maximize the profile likelihood with respect to β1 and β2 analytically,
holding ρ and σ1 as constants using their estimates from the previous EM iteration.
We take the partial derivatives of the conditional expectation (4.1) with respect to
β1 and β2, and set each equal to zero, creating two matrix equations that are linear















Xt1Y1 − ρσ1Xt1X2β̂2 − ρσ1Xt1f(Z1,C)




where C = −X2β̂2, Z1 = (Y1 −X1β̂1)/σ̂1 and














In the function f , the negative ones are multiplied only by the rows of the argument
vectors for which y2i = 0. We solved this system of equations using R.
The next step is to take the solutions, which we call
ˆ̂
β, and substitute them
for β1 and β2 in (4.1). We now optimize with respect to ρ and σ1, using the optim()
function in R. The L-BFGS-B method of optim() is a quasi-Newton algorithm which
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allows one to specify an upper and lower bound for each variable (R 2007). We take
the values returned by optim(), ˆ̂ρ and ˆ̂σ1, and substitute them in (4.6) for ρ and
σ1, respectively. This begins the next cycle of the M-step. We wrote this two-step






t be the values of the estimates of β1 and β2 computed on
the ith iteration of the M-step algorithm, and [ˆ̂ρi, ˆ̂σ1,i]
t be the values of the estimates
of ρ and σ1 computed on the i









































































After the M-step has converged to a set of parameter estimates, θ̂ is updated
with those values, completing one iteration of the EM cycle. Next a new E-Step
begins. The conditional expectation (4.1) and f(Z1,C) are reevaluated using the
updated value of θ̂, and then a new M-Step begins. The EM process is written
in a loop which contains the M-Step loop and repeats until the estimated values
converge. Let
ˆ̂
θi be the value of the estimate of θ computed on the j
th iteration of
the EM algorithm. At each iteration of the EM algorithm, the previous guess was θ̂,
and the current guess is denoted by
ˆ̂






































































4.6 Performance of the Algorithm on Simulated Data
We performed simulations to test the algorithm under varying configurations
of the parameters and correlations between the covariate matrices. We first gen-
erated three independent random samples of size 100 from the standard normal
distribution: U1, U2, and U3. For these covariates, we generated 1000 correlated
Y1 and Y
∗
2 vectors from the following distribution:
Y1 = X1β1 + ε1









with the pairs (ε1i, ε2i) iid, and
















so that the correlation between Y1i and Y
∗
2i is 0.35. We used Y
∗
2 to construct a
vector of binary random variables, Y2, whose i
th row is I{y∗2i > 0}. For each
of the Y1, Y2 vector pairs, we executed our program which calculated maximum
likelihood estimates of β1, β2, and σ1. So, from the same set of covariate matrices,
we have 1000 sets of response vectors and 1000 sets of the corresponding parameter
estimates resulting from our algorithm. For each parameter, we took the sample
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mean of the 1000 estimates and subtracted the true value to compute the bias. We
also computed the sample standard deviations to estimate the standard error of the
estimators, and we calculated an estimate of
√
MSE. The results are displayed in
Table 4.1.
Table 4.1: Results of 1000 MC samples of size 100 with uncorrelated covariates and
ρ = 0.35
Parameter True Value Bias ŝ.e. Bias/s.e.
√
MSE
β1,0 -0.10 -0.005 0.100 -0.051 0.100
β1,1 2.00 -0.002 0.113 -0.020 0.113
β1,2 1.00 0.001 0.089 0.015 0.089
β2,0 0.40 0.050 0.188 0.265 0.194
β2,1 0.70 0.091 0.212 0.429 0.230
β2,2 1.00 0.134 0.229 0.587 0.265
σ1 1.00 -0.017 0.072 -0.230 0.074
ρ 0.35 0.019 0.155 0.122 0.156
Each EM algorithm converged after around 8 iterations. From Table 4.1, we
see that the algorithm gives nearly unbiased estimates of the parameters β1,0, β1,1,
β1,2, σ1, and ρ with relatively small standard error. The estimates of β2,0, β2,1,
and β2,2 show moderate bias. For this simulation, we initialized each θ̂ using the
marginal regression estimates. We also tried starting the algorithm with bad initial
values, but the algorithm continued to produce good estimates, although it used
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more iterations before converging.
We also wanted to compare our estimators with the marginal regression esti-
mators. For each of the Y1 vectors in the simulation, we also computed the least
squares estimates of β1 and σ1, and we ran a probit regression for each Y2 to es-
timate β2. To compare these estimates with those obtained by our program, we
took the ratio of the sample variance of the estimates obtained by the marginal
regression and the sample variance of the estimates obtained by our program. We
also calculated the ratio of the estimated mean squared error for for both estimates.
These quantities are displayed in Table 4.2.
Table 4.2: Comparison of the results of the EM algorithm with the marginal regres-
sion estimates from simulation with ρ = 0.35








From Table 4.2, we see that the MC variances of the initial estimates and final
estimates are similar. We perform the simulation again, with higher correlation
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between Y1 and Y2. Results are presented for uncorrelated, mildly correlated, and
highly correlated covariate matrices in Tables 4.3–4.8. From Table 4.4, we see that
the ratios of the variances for the two estimates are higher now, for the case when
ρ = 0.71.
Table 4.3: Results of 1000 MC samples of size 100 using the same uncorrelated
covariates from Table 4.1 and ρ = 0.71
Parameter True Value Bias ŝ.e. Bias/s.e.
√
MSE
β1,0 -0.10 -0.002 0.101 -0.018 0.101
β1,1 2.00 0.006 0.091 0.061 0.091
β1,2 1.00 0.004 0.090 0.039 0.090
β2,0 0.40 0.096 0.174 0.551 0.199
β2,1 0.70 0.179 0.194 0.924 0.264
β2,2 1.00 0.250 0.235 1.061 0.343
σ1 1.00 -0.015 0.071 -0.215 0.072
ρ 0.71 0.099 0.069 1.437 0.121
In each simulation study, we see that generally V ar(θ̂init)/V ar(θ̂EM) ≥ 1,
and when ρ = 0.71, the gain in efficiency can be substantial. Similarly, we see that
MSE(θ̂init)/MSE(θ̂EM) ≥ 1, with substantial gain when ρ = 0.71. This suggests
that even after accounting for bias, the EM estimates are more accurate than the
marginal regression estimates.
37
Table 4.4: Comparison of the results of the EM algorithm with the marginal regres-
sion estimates from a simulation with ρ = 0.71 and uncorrelated covariates








4.7 Estimating Standard Errors Using Bootstrap
The EM algorithm does not have a built-in facility to estimate the covariance
matrix of the parameters. We can use bootstrap resampling to estimate the standard
errors of the estimates.
Suppose one wants to estimate the standard error of a statistic. The statistic
is computed based on a given dataset; its value is denoted as θ̃. Bootstrapping is
a resampling procedure in which rows of the n × k data matrix are sampled with
replacement to form a new data matrix of the same dimension as the original. The
statistic is computed for this new dataset. This is repeated r times to obtain r values
of the statistic, denoted θ∗1, θ
∗
2, . . . , θ
∗
r . The sample mean and sample variance of
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Table 4.5: Results of 1000 MC samples of size 100 using mildly correlated covariates
(U3 = 0.3U1 − 0.4U2 + ε, εi ∼ N(0, 1)) and ρ = 0.71
Parameter True Value Bias ŝ.e. Bias/s.e.
√
MSE
β1,0 -0.10 -0.001 0.101 -0.007 0.101
β1,1 2.00 -0.003 0.086 -0.033 0.087
β1,2 1.00 -0.002 0.115 -0.018 0.115
β2,0 0.40 0.092 0.168 0.549 0.191
β2,1 0.70 0.153 0.187 0.818 0.241
β2,2 1.00 0.222 0.241 0.921 0.327
σ1 1.00 -0.020 0.069 -0.287 0.072
ρ 0.71 0.100 0.063 1.587 0.118
these r values are computed. The bias of the statistic is estimated as the sample
mean of the θ∗ values minus θ̃, and the standard error of the statistic is estimated
by the sample standard deviation of the θ∗ values.
We used simulated data to check the performance of the bootstrap standard
error estimates against the the estimates from our simulation. We simulated X1
and X2 and 1000 observations of Y1 and Y
∗
2 in manner identical to that described
Section 4.6, and we computed the EM estimates for each simulated dataset, which
we used to compute standard error estimates. On each simulated dataset, we also
drew 200 bootstrap samples, which we used to compute standard error estimates.
The calculations were performed using the R function boot(). We present the results
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Table 4.6: Comparison of the results from a simulation with ρ = 0.71 and mildly
correlated covariates









We assume the Monte Carlo estimates are accurate, since they result from 1000
datasets, and we compare the bootstrap estimates to the MC estimates. We see from
the table that there are some differences. The bootsrap grossly overestimated the
standard error of the estimate for β2,0, β2,1, and β2,2, and underestimated their
biases.
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Table 4.7: Results of 1000 MC samples of size 100 using highly correlated covariates
(U3 = −0.7U1 − 0.8U2 + ε, εi ∼ N(0, 1)) and ρ = 0.71
Parameter True Value Bias ŝ.e. Bias/s.e.
√
MSE
β1,0 -0.10 0.004 0.106 0.035 0.106
β1,1 2.00 0.002 0.106 0.022 0.106
β1,2 1.00 0.003 0.080 0.043 0.080
β2,0 0.40 0.093 0.177 0.527 0.200
β2,1 0.70 0.178 0.233 0.766 0.293
β2,2 1.00 0.261 0.271 0.962 0.377
σ1 1.00 -0.021 0.069 -0.301 0.072
ρ 0.71 0.101 0.068 1.476 0.122
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Table 4.8: Comparison of the results from a simulation with ρ = 0.71 and highly
correlated covariates









Table 4.9: Comparison of Standard Error and Bias Estimates from Monte Carlo
Simulation and Bootstrap Using Slightly Correlated Covariates: (U3 = 0.3U1 −
0.4U2 + ε, εi ∼ N(0, 1)) and ρ = 0.35
Parameter True Value MC Bias BS Bias MC ŝ.e. BS ŝ.e.
β1,0 -0.1 -0.001 0.000 0.100 0.099
β1,1 2 0.001 0.000 0.114 0.114
β1,2 1 -0.002 0.000 0.113 0.113
β2,0 -0.4 0.043 0.027 0.175 0.242
β2,1 0.7 0.078 0.056 0.199 0.323
β2,2 1 0.127 0.089 0.257 0.448
σ1 1 -0.018 -0.017 0.069 0.068
ρ 0.35 0.038 0.008 0.143 0.139
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Chapter 5
Results of Multiple Endpoint Analysis of Prostate Data
From Chapter 3, we have three endpoints of interest. One is the log of prostatic
acid phosphatase (PAP) as measured at follow-up, or logpap2. The second is an
indicator of death due to cancer, metastases, or a change in treatment, which we
call ‘binend.’ The third is an indicator of death due to cardiovascular disease, called
‘carddeath.’ In Section 4.6 we saw that our EM program estimates the regression
parameters with reasonable accuracy when the data are normally distributed. Here
we give the results of our program when applied to the prostate cancer data.
5.1 The Joint Model for Log of PAP and Binend
In Section 3.5 we developed a linear model for the response logpap2 as a func-
tion of logpap at baseline, dose, dose squared, and age. We used probit regression
to model binend as a function of logpap at baseline, surface area of the prostate,
dose, and hemoglobin, so that the two models are
logpap2 = β0 + β1 logpap + β2 dose + β3 dose
2 + β4 age + error
P [binend = 1] = Φ(β0 + β1 logpap + β2 surface area + β3 dose + β4 hemoglobin).
Tables 5.1 and 5.2 give the results of the joint model with logpap2 and binend
including and excluding, respectively, the 70 patients with questionable values of
PAP recorded. The estimates from the separate regressions, which were given in
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Chapter 3, are given, along with the EM estimates and standard errors as estimated
by bootstrap resampling. The EM estimates are close to those estimated using
regression, with the exception of the dose coefficient for the binend model in Table
5.2. Excluding the 70 patients had the effect of changing both intercept terms.
The estimates of ρ are different in the two cases also, but in both cases positive and
significantly different from zero. For the predictors of logpap2, the dose coefficient is
negative, and even after one accounts for the dose squared term, which is positive,
the higher the dose of DES, the lower the logpap2, but the effect lessens as the
dose increases, because the squared term has a positive coefficient. Even over the
short period of six months, the estrogen is reducing the PAP levels. The estimated
standard error for the dose coefficient in the logpap2 model is fairly high, but we
saw in Section 4.6 that the bootstrap tends to overestimate standard errors. Age
had a negative coefficient in both cases, which could be explained by the slower
progression of cancer in older patients. Its effect was only significant in the model
excluding the 70 patients.
As a predictor of binend, dose is not significant regardless of whether we include
or exclude the 70 patients with questionable values of PAP at follow-up, but this
may be because we only have the statuses of patients as of about 6 months after
beginning treatment. The immediate effect of dose on logpap2 does not carry over
to the endpoint binend. Hemoglobin was a significant predictor of binend in the
model including those 70 patients, but not the one excluding them, but surface area
of the prostate was significant for both cases.
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Table 5.1: EM results for joint model of logpap2 and binend, including the 70
patients with imputed values of logpap2
Parameter GLM Est. EM Est. BS Bias BS ŝ.e. p-val∗
Coefficients for logpap2 regression
logpap2 int. 0.975 1.102 0.073 0.601 0.0668
logpap 0.692 0.691 -0.002 0.046 0.0000
age -0.011 -0.013 -0.001 0.008 0.1130
dose -0.987 -0.962 -0.001 0.174 0.0000
dose squared 0.152 0.148 0.000 0.033 0.0000
Coefficients for binend regression
binend int. -0.162 -0.102 -0.047 0.506 0.8407
logpap 0.123 0.118 -0.005 0.048 0.0138
dose 0.024 0.030 -0.001 0.036 0.4010
surface area 0.018 0.015 0.001 0.006 0.0135
hemoglobin -0.082 -0.084 0.002 0.038 0.0273
σ1 0.989 0.983 -0.006 0.047 0.0000
ρ ? 0.270 0.007 0.064 0.0000
* Two-sided p-value based on a Wald test
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Table 5.2: EM results for joint model of logpap2 and binend, excluding the 70
patients with imputed values of logpap2
Parameter GLM Est. EM Est. BS Bias BS ŝ.e.
Coefficients for logpap2 regression
logpap2 int. 1.461 1.412 0.061 0.675
logpap 0.672 0.672 0.004 0.053
age -0.017 -0.017 -0.001 0.009
dose -1.068 -1.061 0.000 0.184
dose squared 0.159 0.157 0.000 0.036
Coefficients for binend regression
binend int. -0.785 -0.755 -0.027 0.740
logpap 0.142 0.137 0.000 0.056
dose -0.011 0.002 -0.005 0.049
surface area 0.022 0.021 0.001 0.007
hemoglobin -0.063 -0.064 0.000 0.054
σ1 1.039 1.032 -0.010 0.056
ρ ? 0.174 -0.002 0.085
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5.2 The Joint Model for Log of PAP and Cardiovascular-Related
Death
Our other binary endpoint was cardiovascular-related death, or carddeath,
which we modeled using a probit regression with age, dose, and history of cardio-
vascular disease as covariates. We used our EM program to jointly model the two
endpoints carddeath and logpap2:
logpap2 = β0 + β1 logpap + β2 dose + β3 dose
2 + β4 age + error
P [carddeath = 1] = Φ(β0 + β1 cardio disease + β2 age + β3 dose).
The results are displayed in Tables 5.3 and 5.4. Again, the estimates from the EM
program are not very different from those obtained by fitting separate regression
models. Including or excluding the 70 patients with imputed values of PAP makes a
big difference. The estimate of ρ without those patients is not significantly different
from zero, while the estimate computed with those patients is significant, with a
z-score of about 3.8. The coefficient estimates for the predictors of logpap2 were
similar to those obtained in the joint model for binend and logpap2.
As a predictor for cardiac death, dose has a significant effect if we include the
70 patients in the analysis, but not if we exclude them. This may be because of
the comparatively high number of deaths among those 70 patients that we noted
in Section 3.2, so that excluding them suppresses evidence of the effect of dose on
cardiac-related death. The coefficient of the term indicating a history of cardio-
vascular disease had a very high standard error, causing it to not be significant,
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whether or not those patients were included in the analyses. This may be because
patients who already had a history of cardiovascular disease were being monitored
and possibly medicated because of the concerns raised in Study 1 of the VACURG
studies about cardiovascular event risks associated with DES.
5.3 Summary
We can see that in this study it makes a difference whether or not the 70
patients with questionable values of logpap2 are included in the analyses. The one
observation of theirs that is in question is the value of PAP measured at follow-up,
and we have seen that whether or not we include them does not make a big difference
on the estimates of the predictors of logpap2. For this reason, we are inclined to
trust the estimates based on including them in the analysis, because they include
more observations. Having said that, we conclude that the drug DES significantly
reduces PAP, increases the probability of cardiovascular-related death, but does not
influence binend, at least over the initial six months of treatment. After observing
the patients over the course of the entire study, Byar (1973) recommended that
treatment be withheld until the patient’s symptoms require relief, and at that time
taking the 1 mg dose.
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Table 5.3: EM results for joint model of logpap2 and carddeath, including the 70
patients with imputed values of logpap2
Parameter GLM Est. EM Est. BS Bias BS ŝ.e. p-val∗
Coefficients for logpap2 regression
logpap2 int. 0.975 0.966 -0.055 0.608 0.1118
logpap 0.692 0.694 0.002 0.046 0.0000
age -0.011 -0.011 0.001 0.008 0.1842
dose -0.987 -0.967 -0.021 0.165 0.0000
dose squared 0.152 0.148 0.005 0.031 0.0000
Coefficients for carddeath regression
carddeath int. -6.230 -6.163 -0.244 1.590 0.0001
cardio dis. hist. 1.018 0.999 0.235 0.987 0.3112
dose 0.119 0.101 0.001 0.050 0.0454
age 0.052 0.052 0.000 0.019 0.0057
σ1 0.989 0.982 -0.013 0.051 0.0000
ρ ? 0.297 -0.001 0.078 0.0001
* Two-sided p-value based on a Wald test
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Table 5.4: EM results for joint model of logpap2 and carddeath, excluding the 70
patients with imputed values of logpap2
Parameter GLM Estimates EM Estimates BS Bias BSŝ.e.
Coefficients for logpap2 regression
logpap2 intercept 1.461 1.461 -0.033 0.696
logpap 0.672 0.674 -0.003 0.052
age -0.017 -0.017 0.000 0.009
dose -1.068 -1.068 -0.007 0.191
dose squared 0.159 0.159 0.002 0.036
Coefficients for caddeath regression
carddeath intercept -7.811 -7.697 -1.800 4.422
cardio disease hist. 0.349 0.342 0.533 1.545
dose 0.051 0.043 -0.011 0.222
age 0.074 0.073 0.014 0.046
σ1 1.039 1.032 -0.009 0.055





We have developed an EM algorithm with an analytically–performed E–step
which gives maximum likelihood estimates of regression coefficients, variances, and
correlation for a binary and a continuous response variable. We did a limited sim-
ulation study in which we showed that the algorithm can increase the efficiency
considerably when the two responses are highly correlated. The EM algorithm does
not include estimates of the standard errors, so we used the bootstrap to estimate
them.
We examined a prostate cancer study, but first did some data screening in
which we raised questions about the accuracy of the records for some of the pa-
tients. We found preliminary regression models based on complete–case records.
We fitted the mean log of PAP as a linear function of the predictors, and we used
probit regression to model the incidence of cardiovascular death as a response and
a composite indicator of cancer progression as a response. We found that dose re-
duced PAP and increased probability of cardiovascular–related death, but did not
significantly affect binend, which indicates cancer mortality and progression to stage
IV cancer. Our EM algorithm also showed these results, and it estimated moderate
positive correlation between both logpap2 and binend and logpap2 and carddeath.
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6.2 Possible Topics for Future Research
We used the ordinary bootstrap to estimate the standard errors of the esti-
mates computed by our algorithm, but we saw in our simulation that the bootstrap
tended to overestimate the standard errors of the coefficients of the binary random
variable’s predictors. A logical next step would be to find improved methods of
estimating the standard errors. Improved methods could involve a variation of the
bootstrap by using parametric bootstrap or bootstrapping the residuals. A different
direction would be to calculate the standard errors analytically by using the meth-
ods of Louis (1982) or any of a number presented in the book by McLachlan and
Krishnan (2008).
We have also seen that the estimates of the coefficients of the continuous
variable’s predictors from our algorithm are very close to those computed from the
linear regression. This suggests that we could reduce the dimension of the problem
by only estimating the correlation, ρ, and the coefficients of the binary endpoint’s
predictors, thereby reducing the computation time. Some analytic study is needed to
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